spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  nonalcoholic steatohepatitis 

 HSMN NewsFeed - 6 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 May 2023
NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2023
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2023
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Nov 2022
Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Sep 2022
Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Aug 2022
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2021
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2020
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2020
Acquist Therapeutics Announces New Appointments to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Jan 2020
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Oct 2019
Soliton's Recent Positive Data Increases Potential Fibrotic Indications
Devices Dermatology
 HSMN NewsFeed - 23 Oct 2019
Pliant Therapeutics Announces Strategic Collaboration to Develop Novel Therapies for NASH and Fibrotic Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Oct 2019
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain
Biopharmaceuticals Drug Delivery Surgery FDA
 HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jun 2019
DURECT Announces $15 Million Registered Direct Offering
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 19 Jun 2019
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2019
Cirius Therapeutics Adds to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 1 Apr 2019
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jan 2019
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 9 May 2018
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery Surgery Licensing
 HSMN NewsFeed - 14 Feb 2018
Galmed Announces ARRIVE Study Data
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Nov 2017
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
Devices Endocrinology Venture Capital
 HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2017
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR(R)
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 18 Apr 2017
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 15 Mar 2017
Julie G. Anderson Joins BioVie as Independent Director and Investor
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Sep 2016
Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH
Biopharmaceuticals Gastroenterology Mergers & Acquisitions
 HSMN NewsFeed - 8 Sep 2016
Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Apr 2016
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Apr 2016
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2015
Zafgen Announces Transition of Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jul 2015
Raptor Pharmaceutical Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2015
XTuit Pharmaceuticals Closes $22 Million Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 May 2015
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Oct 2014
Raptor Pharmaceutical Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Mar 2014
Lumena Pharmaceuticals Raises $45 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Aug 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Oct 2007
Liver Health Improves after Bariatric Surgery
Surgery
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
nonalcoholic steatohepatitis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.